In vitro determination of toxicity, binding, retention, subcellular distribution and biological efficacy of the boron neutron capture agent DAC-1

Radiotherapy and Oncology

Volumn 38, Issue 1, 1996, Pages 41-50

  Tilly, Nina ^a   Olsson, Pär ^a   Hartman, Torbjörn ^a   Coderre, Jeffrey ^b   Makar, Michael ^b   Malmquist, Jonas ^c   Sjöberg, Stefan ^c   Pettersson, Jean ^c   Carlsson, Jörgen ^a   Glimelius, Bengt ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BNCT; Cell culture; Clonogenic survival; DAC 1; Dose modifying factors; Effects; LS 174T cells; Neutron irradiation; Radiation; Subcellular fractionation

Indexed keywords

BORON DERIVATIVE; DAC 1; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; PRIORITY JOURNAL;

EID: 0030052772     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-8140(95)01633-3     Document Type: Article

References (22)

1. Andersson, A., Holmberg, A., Carlsson, J., Pontén, J. and Westermark, B. Binding of epidermal growth factor-dextran conjugates to cultured glioma cells. Int. J. Cancer 47: 439-444, 1991.
2. Barth, R.F., Soloway, A.H. and Fairchild, R.G. Boron neutron capture therapy of cancer. Cancer Res. 50: 1061-1070, 1990.
3. Barth, R.F., Soloway, A.H., Fairchild, R.G. and Brugger, R.M. Boron neutron capture therapy for cancer. Cancer 70(12): 2995-3007, 1992.
4. Blakely, E.A., Ngo, F.Q.H., Curtis, S.B. and Tobias, C.A. Heavy-ion radiobiology: cellular studies. Adv. Radiat. Biol. 11: 295-389, 1984.
5. 131I-EGF on cultured human glioma cells. J. Neuro-Oncol. 9: 201-210, 1990.
6. Carlsson, J., Sjöberg, S. and Larsson, B. Present status of boron neutron capture therapy. Acta Oncol. 31: 803-814, 1992.
7. Coderre, J.A., Makar, M.S., Micca, P.L., Nawrocky, M.M., Liu, H.B., Joel, D.D., Slatkin, D.N. and Amols, H.I. Derivations of relative biological effectiveness for the high-LET radiations produced during boron neutron capture irradiations of the 9L rat gliosarcoma in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. 27: 1121-1129, 1993.
8. 10B-neutron capture therapy: enhancement of tumour dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: a theoretical evaluation. Int. J. Radiat. Oncol. Biol. Phys. 11: 831-840, 1985.
9. Fairchild, R.G., Kahl, S.B., Laster, B.H., Kalef-Ezra, J. and Popenoe, E.A. In vitro determination of uptake, retention, distribution, biological efficiacy, and toxicity of boronated compounds for neutron capture therapy: a comparison of porphyrins with sulfhydryl boron hydrides. Cancer Res. 50: 4860-4865, 1990
10. Fowler, J.F. Heavy particles in radiotherapy. In: The Biological Basis of Radiotherapy, pp. 249-266. Editors: G.G. Steel, G.E. Adams and A. Horwich. Elsevier, Amsterdam, 1989.
11. 125I-epidermal-growth-factor in BALB 3T3 cells. J. Biol. Chem. 855: 1239-1241, 1980.
12. Hartman, T. and Carlsson, J. Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy. Radiother. Oncol. 31: 61-75, 1994.
13. Hatanaka, H., Sweet, W.H., Sano K, et al. The present status of boron neutron capture therapy for tumours. Pure Appl. Chem. 63: 373-374, 1994.
14. Lindström, A. and Carlsson, J. Penetration and binding of epidermal growth factor-dextran conjugates in spheroids of human glioma origin. Cancer Biother. 8: 145-158, 1993.
15. Lindström, P., Olsson, P., Malmqvist, J., Pettersson, J., Lemmen, P., Sjöberg, S., Olin, Å. and Carlsson, J. New carborane based compounds for boron neutron capture therapy. Binding and toxicity of ANC-1, DAC-1 and B -Et-11-OMe in cultured human glioma and mouse melanoma cells. Anti-Cancer Drugs 5: 43-52, 1994.
16. Malmquist, J. and Sjöberg, S. Synthesis of 2[2-(3-aminopropyl)-1,2-dicarba-closo-dodecaborane (12)-1-ylmethoxy]-1,3-propanediol, a hydrophilically substituted aminoalkyl-o-carborane. Acta Chem. Scand. 48: 886-890, 1994.
17. Nguyen, T., Brownell, G.L., Holden, S.A., Kahl, S., Miura, M. and Teicher, B.A. Subcellular distribution of various boron compounds and implications for their efficacy in boron neutron capture therapy by Monte Carlo simulations. Radiat. Res. 133: 33-40, 1993.
18. Sharma, R.P. and Edwards, I.R. cis-Platinum: subcellular distribution and binding to cytosolic ligands. Biochem. Pharmac. 32: 2665-2669, 1983.
19. Sjöberg, S., Hawthorne, M.F., Lindström, P., Malmquist, J., Carlsson, J., Andersson, A. and Pettersson, O. Asymmetric synthesis of carboranyl amino acids with potential use in BNCT. In: Advances in Neutron Capture Therapy, pp. 269-272. Editors: A.H. Soloway et al. Plenum Press, New York, 1993.
20. Sjöberg, S., Carlsson, J., Lindström, P. and Malmquist, J. Carboranyl amino acids and amines with potential use in BNCT. In: Current Topics in the Chemistry of Boron, pp. 173-176. Editor: G.W. Kabalka. Royal Society of Chemistry, Cambridge, 1994.
21. Stenerlöw, B., Carlsson, J., Blomquist, E. and Erixon, K. Clonogenic cell survival and rejoining of DNA double-strand breaks: comparisons between three cell lines after photon or He ion irradiation. Int. J. Radiat. Biol. 65: 631-639, 1994.
22. Uhrberg, R. Acid digestion bomb for biological samples. Anal. Chem. 54: 1906-1908, 1982.